Analytical Data
-
Gene name
CD8b
- Application
-
Alternative Names
CD8b；CD8B1；T-cell surface glycoProtein CD8 beta chain
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10966
-
Expression Region
1-182aa
-
AA Sequence
MALPVTALLL PLALLLHAAR PSQFRVSPLD RTWNLGETVE LKCQVLLSNP TSGCSWLFQP RGAAASPTFL LYLSQNKPKA AEGLDTQRFS GKRLGDTFVL TLSDFRRENE GYYFCSALSN SIMYFSHFVP VFLPAKPTTT PAPRPPTPAP TIASQPLSLR PEACRPAAGG AVHTRGLDFA CD
-
Molecular Weight
22 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD8b is a crucial component of the CD8 glycoprotein family, primarily expressed on cytotoxic T lymphocytes (CTLs). It plays a fundamental role in the immune response by aiding in the recognition of major histocompatibility complex (MHC) class I molecules, which present endogenous antigens. This interaction is critical for the activation and proliferation of CTLs, enabling them to effectively target and eliminate infected or malignant cells. Research into CD8b recombinants has gained momentum in recent years due to its implications in immunotherapy and vaccine development. Studies have shown that enhancing CD8b expression or functionality can improve the anti-tumor responses in various cancer models. Additionally, recombinant CD8b proteins can be utilized as tools to investigate T cell receptor (TCR) interactions and identify novel epitopes for vaccine design. Understanding the structural and functional characteristics of CD8b can provide insights into T cell development and differentiation. Moreover, as CD8b is involved in immune evasion mechanisms employed by tumors and pathogens, targeting CD8b could open new avenues for therapeutic interventions. The ongoing exploration of CD8b recombinants not only seeks to elucidate its biological functions but also aims to leverage its properties for enhancing immune responses in clinical applications, marking it as a significant focus in contemporary immunological research.
